Tender Issued for Advanced Proteomic Analysis of Lung Cancer Samples
A new procurement for high-sensitivity proteomic analysis of lung cancer samples underscores how public buyers are scaling next-generation lab capacity.
A new procurement for high-sensitivity proteomic analysis of lung cancer samples underscores how public buyers are scaling next-generation lab capacity.
Follow Tenderlake on LinkedIn for concise insights on public-sector tenders and emerging procurement signals.
A Romanian medical university is seeking high-sensitivity proteomic analysis of lung cancer patient samples, using dual recognition technologies and next-generation sequencing-type DNA detection. The contract points to growing use of outsourced, ultra-detailed molecular profiling across Europe’s public research and health sectors.
On 21st November 2025, Universitatea de Medicina si Farmacie "Iuliu Hatieganu" Cluj-Napoca published a contract notice for proteomic analysis services. The university requires high-sensitivity proteomic analysis of samples from lung cancer patients, combining dual recognition technologies with next-generation sequencing-type DNA detection.
The specification is tightly focused on performance rather than on particular brands or platforms. By calling for “high-sensitivity” proteomic analysis and dual recognition technologies, the university signals a need to detect and confirm protein signals in complex patient material. The reference to next-generation sequencing-type DNA detection suggests that sequencing-based readouts will sit alongside protein-level measurements in the same workflow.
The notice is framed as a services requirement rather than an equipment purchase. This places the emphasis on specialist providers able to run advanced assays on clinical samples, rather than on expanding in-house hardware. For suppliers, it points to demand for integrated capabilities that span proteomics, sequencing-based detection and the handling of patient-derived material.
The Romanian contract sits within a growing cluster of public procurements for high-end proteomics, genomics and metabolomics across Europe. Throughout June 2025, several buyers issued contracts that echo the same shift towards outsourced, data-rich analysis.
In June 2025, Helmholtz-Zentrum für Infektionsforschung GmbH published a contract notice for metabolomics analysis services, specifying DNA sequencing for the measurement of metabolites from 272 samples. Later that month, Univerzita Pavla Jozefa Šafárika v Košiciach sought an UHPLC/PDA/MS chromatograph to support a high-performance laboratory for analysing molecular forces in protein modifications, underlining the investment in core analytical infrastructure.
By July 2025, this was expanding into full proteomics platforms. On 14th July 2025, the Secretaría General de la Agencia Estatal Consejo Superior de Investigaciones Científicas launched a contract for the supply and installation of advanced proteomics equipment at the Andalusian Center for Molecular Biology and Regenerative Medicine. On the same date, Aalborg University issued a call for molecular profiling of pre-diagnostic inflammatory bowel disease serum samples, seeking two suppliers to deliver genetic and epigenetic profiling alongside metabolomic and proteomic profiling.
As 2025 progressed, proteomics-specific service contracts became more common. In September 2025, Centro Nacional de Investigaciones Cardiovasculares Carlos III (F.S.P.) advertised an NGS proteomic analysis service for oligonucleotide tags in plasma samples, with an emphasis on expedited turnaround. Later that month, Ludwig-Maximilians-Universität München sought a qualified proteomics company to conduct high-throughput quantitative protein analyses of human plasma to identify proteins linked to healthy ageing and to help establish a proteomics laboratory at CALA.
Around the same time, Karolinska Institutet issued a contract notice for surface proteome profiling of cells, underscoring the interest in mapping proteins at the cell surface. Together, these examples show proteomics moving from occasional specialist projects to a more routine component of public-sector research procurement.
The Romanian lung cancer contract is one of many oncology-focused tenders that rely on similar technologies. In August 2025, Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III launched a metabolomic profiling service to characterise plasma and stool samples from women with metastatic breast, lung or colorectal cancer, integrating metabolomic data into a wider study.
Several buyers are concentrating on genomic characterisation of tumours. On 30th September 2025, Fundación para la Investigación Biomédica del Hospital 12 de Octubre published a notice for a tumour genomic determination service to analyse genomic alterations in solid tumours and identify suitable molecular therapies based on evidence scales. On 4th December 2025, МЕДИЦИНСКИ УНИВЕРСИТЕТ - ПЛОВДИВ went to market for next-generation sequencing services covering whole exome and targeted sequencing of genomic and tumour DNA to support cancer diagnosis and treatment.
Other buyers are building out the consumables and software needed to sustain this activity. In August 2025, Lietuvos sveikatos mokslų universitetas (PV) tendered for protein analysis reagent kits for oncology testing. In November 2025, Lietuvos sveikatos mokslų universiteto ligoninė Kauno klinikos (PV) sought reagents and tools for tumour sequencing tests, together with a laboratory system for next-generation sequencing available for lease.
There is also a strong emphasis on enabling detailed characterisation of specific cancers. On 28th July 2025, Państwowy Instytut Medyczny Ministerstwa Spraw Wewnętrznych i Administracji launched a contract for genomic and transcriptomic analysis of glioblastoma tissue samples. In November 2025, Dolnośląskie Centrum Onkologii, Pulmonologii i Hematologii issued a wide-ranging notice for laboratory supplies and software licences to support genetic variant analysis and molecular diagnostics across several cancers.
Suppliers of consumables are also in focus. On 24th November 2025, the Macedonian Academy of Sciences and Arts advertised a contract for kits and reagents for sequencing oncology and cancer gene panels, including single cell kits, polymerases, buffer containers and specialised oligonucleotides. This kind of backbone procurement enables the kind of sequencing-based detection also referenced in the Romanian proteomics contract.
While the subject matter ranges from lung cancer to inflammatory bowel disease and healthy ageing, several procurement patterns are emerging from these notices.
First, buyers are mixing service contracts with investment in core equipment. The Romanian university, CNIC in Spain and LMU München have all opted for external proteomic analysis services, whereas the Andalusian center and Univerzita Pavla Jozefa Šafárika v Košiciach are acquiring high-end instruments for long-term in-house use. Suppliers need to decide whether they position themselves as service providers, equipment manufacturers, or partners able to bridge both.
Second, there is sustained demand for reagents and software tightly matched to existing platforms. In July 2025, HUS-yhtymä’s Laboratory of Genetics sought Mastermix/Supermix reagents for large-scale quantitative PCR testing, with explicit requirements for compatibility with certain pipetting robots and Real-Time PCR cyclers. In October 2025, Etablissement français du sang published a notice for HLA typing reagents and interpretation software for high-resolution typing on specific next-generation sequencing platforms.
Third, some organisations are flagging their procurement needs early. In September 2025, the Leibniz-Institut für Analytische Wissenschaften - ISAS - e.V. issued a prior information notice for high-resolution LC-MS/MS systems to analyse clinical samples with high sensitivity and broad molecular coverage. In October 2025, Karolinska Universitetssjukhuset published a prior information notice seeking technical solutions for multi-biomarker gene panel analysis in tumour profiling using next-generation sequencing. These early signals allow suppliers to prepare for forthcoming competitions.
The Romanian university’s requirement for dual-recognition, next-generation sequencing-type proteomic analysis in lung cancer patients adds another data point to a clear trend: public buyers are no longer treating advanced omics as exceptional projects, but as standard tools to answer clinical and research questions.
Upcoming competitions inspired by current prior information notices, and new calls such as the Greek contract for transcriptomics-based analysis of biological samples, will show how far buyers move towards fully integrated multi-omics workflows. For now, the latest lung cancer proteomics tender in Cluj-Napoca confirms that high-sensitivity, sequencing-enabled analysis has firmly entered the mainstream of public-sector procurement.
Follow Tenderlake on LinkedIn for concise insights on public-sector tenders and emerging procurement signals.